ErbB Receptors: Directing Key Signaling Networks Throughout Life

Annual Review of Pharmacology and Toxicology

Volumn 44, Issue , 2004, Pages 195-217

  Holbro, Thomas ^a   Hynes, Nancy E ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Cancer therapy; EGFR; ErbB2; Signaling pathways

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOPHENOL MONOOXYGENASE; PHOSPHOTRANSFERASE;

DIMERIZATION; EMBRYO DEVELOPMENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

AGING; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; MUTATION; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 1342323632     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.44.101802.121440     Document Type: Review

References (146)

1. Riese DJ, Stern DF. 1998. Specificity within the EGF family/ErbB receptor family signaling network. BioEssays 20:41-48
2. Olayioye MA, Neve RM, Lane HA, Hynes NE. 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:3159-67
3. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-37
4. Chang C, Sternberg PW. 1999. C. elegans vulval development as a model system to study the cancer biology of EGFR signaling. Cancer Metastasis Rev. 18:203-13
5. Schweitzer R, Shilo BZ. 1997. A thousand and one roles for the Drosophila EGF receptor. Trends Genet. 13:191-96
6. Reich A, Shilo BZ. 2002. Keren, a new ligand of the Drosophila epidermal growth factor receptor, undergoes two modes of cleavage. EMBO J. 21:4287-96
7. Hynes NE, Stern DF. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198:165-84
8. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:183-32
9. Mendelsohn J, Baselga J, 2000. The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-65
10. de Bono JS, Rowinsky EK. 2002. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8:S19-26
11. Massague J, Pandiella A. 1993. Membrane-anchored growth factors. Annu. Rev. Biochem. 62:515-41
12. Seals DF, Courtneidge SA. 2003. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17:7-30
13. Urban S, Lee JR, Freeman M. 2002. A family of Rhomboid intramembrane proteases activates all Drosophila membrane-tethered EGF ligands. EMBO J. 21:4277-86
14. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, et al. 2002. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775-87
15. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, et al. 2002. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110:763-73
16. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:211-25
17. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. 2003. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11: 507-17
18. Cho HS, Leahy DJ. 2002. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297:1330-33
19. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-60
20. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, et al. 2003. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11:495-505
21. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, et al. 1996. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol. 16:5276-87
22. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1647-55
23. Qian XL, O'Rourke DM, Fei ZZ, Zhang HT, Kao CC, Greene MI. 1999. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes. J. Biol. Chem. 274: 574-83
24. Ferguson KM, Darling PJ, Mohan MJ, Macatee TL, Lemmon MA. 2000. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J. 19:4632-43
25. Penuel E, Akita RW, Sliwkowski MX. 2002. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J. Biol. Chem. 277:28468-73
26. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, et al. 1999. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA 96:4995-5000
27. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL III. 1994. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 91:8132-36
28. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE. 1998. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell Biol. 18:5042-51
29. Sweeney C, Lai C, Riese DJ, Diamonti AJ, Cantley LC, Carraway KL III. 2000. Ligand discrimination in signaling through an ErbB4 receptor homodimer. J. Biol. Chem. 275:19803-7
30. Yaffe MB. 2002. Phosphotyrosine-binding domains in signal transduction. Nat. Rev. Mol. Cell Biol. 3:177-86
31. Soltoff SP, Cantley LC. 1996. p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. J. Biol. Chem. 271:563-67
32. Fedi P, Pierce JH, Di Fiore PP, Kraus MH. 1994. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol. Cell Biol. 14:492-500
33. Prigent SA, Gullick WJ. 1994. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13:2831-41
34. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. 1999. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18:2607-15
35. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. 2003. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284:31-53
36. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. 1999. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 96:1415-20
37. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, et al. 1999. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4:1029-40
38. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. 1996. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271:5251-57
39. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, et al. 1998. c-Cbl/ Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 12:3663-74
40. Waterman H, Sabanai I, Geiger B, Yarden Y. 1998. Alternative intracellular routing of ErbB receptors may determine signaling potency. J. Biol. Chem. 273:13819-27
41. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, et al. 1998. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17:3385-97
42. Graus-Porta D, Beerli RR, Hynes NE. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell Biol. 15:1182-91
43. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, et al. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-21
44. Quantin B, Breathnach R. 1988. Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts. Nature 334:538-39
45. Cutry AF, Kinniburgh AJ, Krabak MJ, Hui SW, Wenner CE. 1989. Induction of c-fos and c-myc proto-oncogene expression by epidermal growth factor and transforming growth factor alpha is calcium-independent. J. Biol. Chem. 264:19700-5
46. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, et al. 2000. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19:1647-56
47. Biswas DK, Cruz AP, Gansberger E, Pardee AB. 2000. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA 97:8542-47
48. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, et al. 2000. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J. Biol. Chem. 275:8027-31
49. Alroy I, Soussan L, Seger R, Yarden Y. 1999. Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor. Mol. Cell Biol. 19:1961-72
50. O'Hagan RC, Hassell JA. 1998. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene 16:301-10
51. Jackson JG, Kreisberg JI, Koterba AP, Yee D, Brattain MG. 2000. Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene 19:4574-81
52. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. 1999. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 274:17209-18
53. Holbro T, Civenni G, Hynes NE. 2003. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 284:99-110
54. Yamauchi T, Ueki K, Tobe K, Tamemoto H, Sekine N, et al. 1997. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature 390:91-96
55. Yamauchi T, Yamauchi N, Ueki K, Sugiyama T, Waki H, et al. 2000. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J. Biol. Chem. 275:33937-44
56. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. 1999. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 274:8335-43
57. Carpenter G. 2000. EGF receptor transactivation mediated by the proteolytic production of EGF-like agonists. Science STKE 2000:E1
58. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. 2001. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20:1594-600
59. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, et al. 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884-88
60. Gschwind A, Prenzel N, Ullrich A. 2002. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res. 62:6329-36
61. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, et al. 2002. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8:35-40
62. Yan Y, Shirakabe K, Werb Z. 2002. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J. Cell Biol. 158:221-26
63. Civenni G, Holbro T, Hynes NE. 2003. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep. 4:166-71
64. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, et al. 1995. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269:230-34
65. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, et al. 1995. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337-41
66. Sibilia M, Steinbach JP, Stingl L, Aguzzi A, Wagner EF. 1998. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 17:719-31
67. Mann GB, Fowler KJ, Gabriel A, Nice EC, Williams RL, Dunn AR. 1993. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73:249-61
68. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. 1995. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-98
69. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, et al. 1995. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378:390-94
70. Meyer D, Birchmeier C. 1995. Multiple essential functions of neuregulin in development. Nature 378:386-90
71. Morris JK, Lin W, Hauser C, Marchuk Y, Getman D, Lee KF. 1999. Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron 23:273-83
72. Woldeyesus MT, Britsch S, Riethmacher D, Xu L, Sonnenberg-Riethmacher E, et al. 1999. Peripheral nervous system defects in erbB2 mutants following genetic rescue of heart development. Genes Dev. 13:2538-48
73. Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, Yamaai T, Lewin GR, Birchmeier C. 1997. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 389: 725-30
74. Christiansen JH, Coles EG, Wilkinson DG. 2000. Molecular control of neural crest formation, migration and differentiation. Curr. Opin. Cell Biol. 12:719-24
75. Britsch S, Li L, Kirchhoff S, Theuring F, Brinkmann V, et al. 1998. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev. 12:1825-36
76. Chan R, Hardy WR, Laing MA, Hardy SE, Muller WJ. 2002. The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development. Mol. Cell Biol. 22:1073-78
77. Camenisch TD, Schroeder JA, Bradley J, Klewer SE, McDonald JA. 2002. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat. Med. 8:850-55
78. Luetteke NC, Phillips HK, Qiu TH, Copeland NG, Earp HS, et al. 1994. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 8:399-13
79. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, et al. 2002. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8:459-65
80. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, et al. 2002. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA 99:8880-85
81. Andrechek ER, Hardy WR, Girgis-Gabardo AA, Perry RL, Butler R, et al. 2002. ErbB2 is required for muscle spindle and myoblast cell survival. Mol. Cell Biol. 22:4714-22
82. Leu M, Bellmunt E, Schwander M, Farinas I, Brenner HR, Muller U. 2003. Erbb2 regulates neuromuscular synapse formation and is essential for muscle spindle development. Development 130:2291-301
83. Garratt AN, Voiculescu O, Topilko P, Charnay P, Birchmeier C. 2000. A dual role of ErbB2 in myelination and in expansion of the Schwann cell precursor pool. J. Cell Biol. 148:1035-46
84. Murillas R, Larcher F, Conti CJ, Santos M, Ullrich A, Jorcano JL. 1995. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J. 14:5216-23
85. Stern DF. 2003. ErbBs in mammary development. Exp. Cell Res. 284:89-98
86. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, et al. 1984. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521-27
87. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. 1997. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 8:1197-206
88. Ekstrand AJ, Sugawa N, James CD, Collins VP. 1992. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 89:4309-13
89. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. 1996. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78:1284-92
90. Klijn JG, Berns PM, Schmitz PI, Foekens JA. 1992. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 13: 3-17
91. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E, 1997. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3:515-22
92. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, et al. 1996. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 73:301-6
93. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, et al. 1987. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51: 1063-70
94. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, et al. 1998. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 90:824-32
95. Hsieh ET, Shepherd FA, Tsao MS. 2000. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. Lung Cancer 29:151-57
96. Nicholson RI, Gee JM, Harper ME. 2001. EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl. 4):S9-15
97. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-12
98. Lemoine NR, Jain S, Silvestre F, Lopes C, Hughes CM, et al. 1991. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br. J. Cancer 64:79-83
99. Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, et al. 1993. Heterogeneity of ErbB-2 gene amplification in bladder cancer. Cancer Res. 53:2199-203
100. Ross JS, Fletcher JA. 1998. The HER2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413-28
101. Noonberg SB, Scott GK, Hunt CA, Hogan ME, Benz CC. 1994. Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides. Gene 149:123-26
102. Beerli RR, Dreier B, Barbas CF III. 2000. Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA 97:1495-500
103. Roh H, Pippin JA, Green DW, Boswell CB, Hirose CT, et al. 2000. HER2/neu antisense targeting of human breast carcinoma. Oncogene 19:6138-43
104. Juhl H, Downing SG, Wellstein A, Czubayko F. 1997. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. J. Biol Chem. 272:29482-86
105. Basso AD, Solit DB, Munster PN, Rosen N. 2002. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159-66
106. Fry DW. 2003. Mechanism of action of erbB tyrosine kinase inhibitors. Exp. Cell Res. 284:131-39
107. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, et al. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2053-63
108. Moasser MM, Basso A, Averbuch SD, Rosen N. 2001. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61:7184-88
109. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, et al. 2002. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62:2554-60
110. Huang SM, Li J, Armstrong EA, Harari PM. 2002. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 62:4300-6
111. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. 1995. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1:1311-18
112. Sunada H, Magun BE, Mendelsohn J, MacLeod CL. 1986. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. USA 83:3825-29
113. Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, et al. 1996. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397-403
114. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. 1996. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56:3666-69
115. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. 1995. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. 95:1897-905
116. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ. 1998. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin. Cancer Res. 4:2957-66
117. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, et al. 1999. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5:257-65
118. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, et al. 2000. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6: 4874-84
119. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. 1989. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9:1165-72
120. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26:60-70
121. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. 2000. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell Biol. 20:3210-23
122. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. 2002. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62:4132-41
123. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825-31
124. Clynes RA, Towers TL, Presta LG, Ravetch JV. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443-46
125. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639-48
126. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-92
127. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, et al. 2002. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20:1215-21
128. Azzoli CG, Krug LM, Miller VA, Kris MG, Mass R. 2002. Trastuzumab in the treatment of non-small cell lung cancer. Semin. Oncol. 29:59-65
129. Herbst RS, Hong WK. 2002. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin. Oncol. 29:18-30
130. Arteaga CL, Johnson DH. 2001. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr. Opin. Oncol. 13:491-98
131. Wilkinson E. 2002. Surprise phase III failure for ZD1839. Lancet Oncol. 3: 583
132. Thor AD, Liu S, Edgerton S, Moore D, Kasowitz KM, et al. 2000. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18:3230-39
133. DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, et al. 2002. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res. 62:6667-73
134. a. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, et al. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100: 8933-38
135. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, et al. 2002. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-37
136. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, et al. 2002. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20:110-24
137. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. 2002. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105:1551-54
138. Behr TM, Behe M, Wormann B. 2001. Trastuzumab and breast cancer. N. Engl. J. Med. 345:995-96
139. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, et al. 1995. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55:5536-39
140. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. 1996. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6:217-23
141. Umekita Y, Ohi Y, Sagara Y, Yoshida H. 2000. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int. J. Cancer 89:484-87
142. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-82
143. Falck VG, Gullick WJ. 1989. c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. J. Pathol. 159:107-11
144. Stenman G, Sandros J, Nordkvist A, Mark J, Sahlin P. 1991. Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer 3:128-35
145. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. 1991. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer 27:1372-75
146. Traxler P. 2003. Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin. Ther. Targets 7:215-34